Navigation Links
ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease
Date:8/19/2008

Donated blood and tissue samples to be used to identify molecular signature of motor neuron disease

CAMBRIDGE, Mass., Aug. 19 /PRNewswire-USNewswire/ -- ALS Therapy Development Institute (ALS TDI) announced today the acceleration of an ALS biomarker effort using blood samples collected through an expanded network of clinical partnerships. These ongoing projects are part of the Institute's extensive effort to indentify the altered expression of genes and proteins, at the onset of, and throughout the progression of the fatal neurodegenerative disease known as amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease). The knowledge generated through this effort will be crucial to the identification of potential biomarkers which could be used for diagnosis and monitoring of disease progression, and will be useful for researchers worldwide in the effort to develop truly effective therapeutics. To facilitate additional ALS patient participation, ALS TDI has recently executed or submitted protocols to several additional hospitals and clinics for the collection of additional blood samples, as well as muscle and adipose tissue. The program is designed to include all ALS patients, regardless of whether they have a sporadic or inherited form of the disease.

"These types of ongoing projects, made possible only through collaborations with our clinical partners, are critical to determining the molecular signatures of this extremely complicated disease. The efforts of our clinical partners to carefully collect these biological samples, as well as the relevant clinical information from each patient, is central for the success of this project," said Steve Perrin, Ph.D., chief scientific officer of ALS TDI.

ALS is a neurodegenerative disease resulting in progressive paralysis and is considered fatal. The disease typically strikes without an identifiable cause, indiscriminately affecting a new family every 90 minutes in the U.S. That i
'/>"/>

SOURCE ALS Therapy Development Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... Nov. 20, 2014  RedRick Technologies, a provider ... reading room environment guidance, has helped the new ... reading room, which may also serve as a ... Medicine. "In line with the ... of Radiology,s Imaging 3.0 ™ initiative, the ...
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at Citi,s 2011 Global Health Care ... presentation takes place on Tuesday, March 1, 2011 at 2:00 ... will be webcast and may be accessed on the Company,s ...
... Ortho Biotech Inc. (Centocor) today received a decision from ... Washington, D.C. overturning a 2009 federal court jury verdict ... Laboratories liable for patent infringement. A panel ... Centocor anti-tumor necrosis factor (TNF) -alpha rheumatoid arthritis treatments ...
Cached Medicine Technology:Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc. 2
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... 2014 The FDA is Watching: , ... On-Demand Webinar**, Dec. 11, 2014 ? Any Time at ... focus on promotional activities is no longer limited to ... looking at websites, Twitter, journal articles, TV appearances, Facebook ... Dec. 11, for On-Demand access to Timothy Ayers and ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Every year ... their communities. AlignLife experience rapid growth in the Greenville, ... very unique opportunity. AlignLife of Simpsonville will ... offices for their first annual Toy Drive. These six ... they would support with this year's toy drive. With ...
(Date:11/22/2014)... black prom dress will never go out of fashion. BellasDress.com, ... new items of black prom gowns . Now all ... up to 70% off. People throughout the world can enjoy ... made with the best materials, can make wearers feel comfortable. ... company provides these beautiful outfits in a huge range of ...
(Date:11/22/2014)... 22, 2014 “Due to my knee replacement ... from Gurnee, Ill. “While using the ice grip attachment, I ... thought there needed to be a safer way to prevent ... BLOCK. , The SPIKE BLOCK offers added safety and stability ... help to reduce injuries and damage associated with traditional spiked ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... new drug targets for mucosal fungus found in most ... genetic approach to improve treatment of common infections caused by ... by researchers at Georgetown University Medical Center. , The ... Ssk1 gene could offer a new drug target against the ...
... who report receiving written and verbal instructions on the ... significantly less likely to suffer the serious gastrointestinal and ... the drug, according to new research from the University ... the October issue Journal of General Internal Medicine ...
... Breast Cancer Funding to be a National Priority, DALLAS, ... Day,the Susan G. Komen for the Cure(R) Advocacy Alliance today ... -- that features a,bipartisan collection of voters declaring "I ... us in some way, and Americans all across,the country have ...
... American National,Insurance Company (Nasdaq: ANAT ) announced a ... share) compared to net income of,$79,245,000 ($2.98 per diluted ... security investments as well as,catastrophe losses in the property ... in earnings., After tax operating earnings for the ...
... Care, Inc. (DCI),announced today that it has completed ... PANCRECARB(R) (pancrelipase), used in the treatment,of Exocrine Pancreatic ... ("FDA"). The FDA had previously granted the product ... schedule., "Digestive Care has provided vital products ...
... providing the industry,s most aggressive defense, The Doctors Company, the largest ... is rolling out litigation education retreats for member physicians who are ... ... Calif. (Vocus) October 27, 2008 -- As part of its commitment ...
Cached Medicine News:Health News:Genetic Approach Boosts Yeast Infection Treatment 2Health News:Better instructions reduce complications among patients using common blood thinner 2Health News:Better instructions reduce complications among patients using common blood thinner 3Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Unveils New 'I Vote for the Cure'(R) Web Video 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Unveils New 'I Vote for the Cure'(R) Web Video 3Health News:American National Announces Third Quarter 2008 Results 2Health News:American National Announces Third Quarter 2008 Results 3Health News:American National Announces Third Quarter 2008 Results 4Health News:Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase) 2Health News:The Doctors Company Launches Litigation Education Retreats to Assist Physicians Involved in Medical Litigation 2
7 mm blade, angled right. Flat handle....
5 mm blade with slightly rounded tip. Round handle....
0.75 mm diameter blade. Angled 60 degrees. Round handle. Designated most popular model or size....
7 mm strong curved blade. Round handle....
Medicine Products: